The Journal of family practice
-
YES. Augmentation with second generation antipsychotics, especially aripiprazole and quetiapine, appears to be effective in patients with moderate-to-severe depression who have had a suboptimal response to a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor (strength of recommendation [SOR]: A, based on a systematic review of randomized controlled trials [RCTs] and an individual RCT). Augmenting antidepressant therapy with cariprazine, ziprasidone, or olanzapine also appears to improve depressive symptoms over the short term. All antipsychotics studied carried an increased likelihood of adverse effects that could lead to discontinuation (SOR: A, based on a systematic review of RCTs).
-
Asthma remains a substantial health burden, despite continued treatment advances. Patients with mild or moderate asthma, even those with intermittent symptoms, are at risk for severe or fatal exacerbations. Use of short-acting beta2-agonist (SABA)-only rescue therapy is associated with an increased risk of exacerbations, beginning at about the second fill annually. ⋯ There is a window of opportunity just prior to an asthma exacerbation during which use of fast-acting bronchodilator + ICS may play a significant role in mitigating the risk of exacerbation. Patients may respond better to a combination inhaler of a fast-acting bronchodilator and an ICS as needed for rescue therapy or as part of a maintenance and rescue therapy paradigm, rather than attempting to use separate inhalers. However, there is currently no fixed-dose, fast-acting bronchodilator + ICS approved in the United States for as-needed use.
-
Key to patients' well-being is the family physician's watchfulness-through periodic lab testing and health checks and diligent application of preventive measures.
-
This UK study revealed the benefits of introducing gluten at age 4 months.
-
The gut microbiome, sometimes referred to as the "organ" we do not know we have, is a dynamic ecosystem that plays an important role in human health and disease. Alterations in the gut microbiome (dysbiosis) are associated with wide-ranging disease states, including metabolic diseases like type 2 diabetes mellitus (T2D). Growing evidence suggests improved gut microbiome composition from targeted microbiome interventions leads to improvement in glycemic control in patients with T2D.